Revista Gastroenterología

January 2020


BRAF inhibition in colorectal cancer:

A combination therapy of the BRAF inhibitors encorafenib and binimetinib plus cetuximab results in significantly longer overall survival and a higher response rate than standard therapy in patients with BRAF V600E-mutated metastatic colorectal cancer.


Primary biliary cholangitis (PBC):

A retrospective cohort study indicates that the addition of bezafibrate to ursodeoxycholic acid monotherapy improves not only GLOBE and UK-PBC scores but also the long-term prognosis. Of note, this benefit is most prominent in those patients with early-stage PBC.

Novel therapeutic strategy in non-alcoholic steatohepatitis (NASH):

Resmetirom is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity. Indeed, a current phase 2 trial demonstrates substantial reduction of hepatic fat after 12 and 36 weeks of treatment with resmetirom.

Cancer risk and non-alcoholic fatty liver disease (NAFLD):

A current longitudinal cohort study demonstrates that NAFLD, but not obesity alone, is associated with an increased cancer risk, particularity of gastrointestinal types. These data suggest that NAFLD may be a mediator of the obesity-cancer association.

Oesophagus Stomach Duodenum


Pancreatic cancer:

Globally, the numbers of deaths and incident cases have more than doubled between 1990 and 2017 and will increase further. Development of screening programs and preventive strategies to control risk factors such as smoking, high plasma glucose as well as high body mass index are urgently needed.



Login to your account below

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.

Estimado Médico
Para tener acceso a artículos exclusivos de la revista gastroenterología

En su suscripción recibirá mensualmente nuestro boletín con noticias, eventos y sesiones en vivo.

Si ya esta registrado ingrese aquí